HealthyNCT02841449
The Effect of Hydration Status on Glycemic Control and Appetite Regulation
A study testing Hypohydrated and Rehydrated in people with Healthy, run by University of Bath at 1 site in United Kingdom.
Trial summary
The aim of this study is to investigate whether hydration status affects blood sugar control and appetite regulation. In order to do this, participants will undergo a monitoring phase whereby their weight, diet and physical activity are monitored, followed by a dehydration protocol involving fluid restriction and… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Hypohydrated and Rehydrated
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jul 2016to Jan 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male or female
- Aged 18-60 years
- Able and willing to give informed consent
Who cannot join
- Any known metabolic or glucose disorder
- Taking necessary medication (other than contraceptives) or supplements that are known to affect glycaemic control (e.g. chromium, PUFAs)
- Current alcohol or drug dependency
- Aged < 18 years, or > 60 years; pregnant or breastfeeding
- Any other factors which are deemed to have the potential to cause harm to the participant and/or could introduce bias into the study
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this study is to investigate whether hydration status affects blood sugar control and appetite regulation. In order to do this, participants will undergo a monitoring phase whereby their weight, diet and physical activity are monitored, followed by a dehydration protocol involving fluid restriction and sitting in a heat tent. In one arm of the trial, participants will remain dehydrated for the remainder of the day (i.e. after the heat tent) by having their fluid intake restricted, and in the other arm of the trial, participants will be rehydrated by consuming the necessary amount of plain water. All participants will undergo both arms of the trial, the order of which will be chosen randomly.
Several measures will be taken throughout the trial. Before participants go into the heat tent, they will provide a urine sample (for baseline hydration status as indicated by urine osmolality), a blood sample (for glucose, insulin, arginine vasopressin,/copeptin, ghrelin and serum osmolality and plasma volume), and have a peripheral quantitative computer tomography scan of their thigh to indicate muscle size. On the day proceeding the heat tent, participants will have these measures repeated, along with metabolic rate before consuming a 75 g glucose drink, followed by 15 minutely blood samples and hourly metabolic rate measures for 120 minutes (i.e. an oral glucose tolerance test; OGTT). Following this, participants will be presented with a large bowl of pasta and sauce and will be instructed to eat until satisfied (maximum 30 min). Blood samples will be taken every 10 minutes for 60 minutes following the meal.
Participants also have the option to opt-in to have a muscle biopsy taken. This will be taken before and ~120 minutes after the glucose drink.
Read the detailed description
The aim of this study is to investigate whether hydration status affects blood sugar control and appetite regulation. This will be a randomised crossover trial with two trial arms separated by 5-35 days. Each trial arm consists of five days in total, with the only difference between the trial arms being the amount of fluid consumed after the heat tent on day 4 (as described below).
Days 1-3 of each trial arm are the monitoring phase. Participants will be given a chest mounted activity monitor (ActiHeart TM), some body mass scales, a food diary with food weighing scales and three urine sample pots. Participants will be required to provide a urine sample upon waking, and note their weight before eating. The activity monitor will need to be worn from midnight on day 1 in order to gauge three full 24-h periods of activity. The food diary will also start at this point; participants will be required to weigh and record all their food and beverages (including recording the leftovers). On day 3 of the monitoring phase, participants will be required to continue their normal daily routine, however they will be provided with a set amount of water to consume (40 mL/kg lean body mass) in order to standardize baseline hydration status. No food or fluid will be allowed to be consumed after 2200 h on day 3.
On day 4, participants will take the same measures (weight and urine sample) and will arrive at the university in a fasted state (i.e. no food or fluid). A blood sample will be drawn from an antecubital vein followed by a peripheral quantitative computer tomography (pQCT) scan of the thigh. After the blood sample and scan, participants may eat food from a list of low water-content foods only for the rest of the day. At approximately midday (flexible depending on the participants' availability, but matched on both trial arms), participants will be weighed again, and placed in a heat tent (40-50 degrees Celsius) until they lose 1 % of their pre-heat tent weight or for a maximum of one hour (whichever comes first). On the second trial arm, participants will be matched by percentage of body mass loss, even if this requires spending more or less time in the heat tent, but still no more than one hour.
After the heat tent, participants will receive a salty meal in order to facilitate fluid absorption/retention. This will be matched in both trial arms in order to reduce confounding. In the dehydration trial arm, participants will be provided with 3 mL/kg lean body mass of plain water to consume for the rest of the day. In the rehydration trial arm, participants will be given 40 mL/kg lean body mass plus 150 % of their body mass losses from the heat tent. This will be metered out throughout the day to maximise rehydration. Thus the amount of water consumed on day 4 after the heat tent is the only discernible difference between the trial arms, with everything else matched. In both trial arms only plain water (i.e. no caffeine or alcohol) will be allowed to be consumed, and only foods from the dry food list can be eaten. This will be matched on the subsequent trial arm. No food or fluid after 2200 h on day 4.
On the fifth day of each trial arm, participants will be required to attend the laboratory at approximately 0730 h (± 1 h). A urine sample will be collected, along with body mass. Another pQCT scan of the thigh will be taken and participants' metabolic rate will be measured using the Douglas bag method. As part of the trial, participants are able to opt-in for a muscle biopsy. If they have opted-in, a muscle biopsy will be taken after the pQCT scan. This will involve a local anesthetic (Lidocaine), making a small incision using a scalpel, then obtaining a muscle sample using the Bergstrom technique. Participants will then be fitted with a cannula, and their hand will be placed in a 60 degree Celsius hotbox for five minutes, after which a baseline blood sample will be drawn. Participants will be given a 75 g glucose drink to consume within five minutes. Whilst remaining rested, a researcher will draw a 10 mL blood sample every 15 minutes for 120 minutes, with approximately 10 mL saline infused after each blood sample drawn. Metabolic rate will be measured at 0 (pre-OGTT), 60 and 120 minutes. For the participants who opted-in for the muscle biopsy, another one will be taken after 120 minutes.
Participants will then be presented with some computer based appetite assessing psychological inventories to assess subconscious food preferences. These tests are pilot data for future research. Following this, participants will be presented with a pasta meal, with the instruction to eat until satisfied for a maximum of 30 minutes. After 30 minutes, a blood sample will be drawn, followed by 10 minutely samples for 60 minutes. Visual analogue scales for subjective appetite ratings will be taken pre-meal, immediately, post-meal, then at 30 and 60 minutes post-meal. The cannula will then be removed.
The sample size required for this trial is 16 participants, calculated using pilot data which assessed blood glucose control after being dehydrated and rehydrated. Based on that pilot study, hydration status resulted in a marked difference in the rate of return to fasted glycaemia. This primary conclusion was supported by a magnitude of effect 45 minutes post-oral glucose tolerance test (D = 1.1 mmol/l). The standard deviation at this time point in the control (normal hydration) group was also 1.1 mmol/l, resulting in an effect size (d) of ≈1. To provide a 95 % power (beta level) to detect this effect at an alpha level (p) of less than or equal to 0.05 using a 2--tailed paired t--test will require ~16 participants.
If any participant does not complete the study (i.e. they have missing data), their data will not be included in the analysis. In other words, the analysis plan will be per protocol (completers only). The statistical techniques used will be linear modelling with post-hoc t-tests corrected for multiple comparisons where relevant. However, until the final dataset has been obtained, the statistical tests may be subject to change (e.g. if data are non-parametric).
- Conditions
- Healthy
- Being tested
- Hypohydrated, Rehydrated
- Keywords
- Hydration, Glycemic control, Appetite, Endocrinology
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HypohydratedBehavioural
Participants remain hypohydrated after the heat tent procedure
RehydratedBehavioural
Participants rehydrate after the heat tent procedure
| Study group | Role | What they receive |
|---|---|---|
| Hypohydrated | Experimental | After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL]) Receives: Behavioral: Hypohydrated |
| Rehydrated | Experimental | After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL). Receives: Behavioral: Rehydrated |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glycemic Response
Primary analysis is time trends (i.e. ANOVA effects), supported by indices of the glycemic response (e.g. iAUC, time to peak). Blood was taken pre-muscle biopsy (if participants opted in for a muscle biopsy), before consuming the glucose drink (after the biopsy, where applicable), then at 15 minutely samples for 120 minutes. After the meal test, blood was drawn at 10 minutely intervals for 60 minutes, starting 30 minutes after commencement of eating.
Measured: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes
Secondary outcomes (8)
Insulinemic Response
Primary analysis is time trends (i.e. ANOVA effects), supported by indices of the insulinemic response (e.g. iAUC, time to peak). Bloods drawn at pre-biopsy, pre-OGTT, 15, 30, 45, 60, 90, 120 min and 0, 30, 60 minutes after the ad libitum meal test.
Measured: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes
Arginine Vasopressin and Copeptin Response
Primary analysis is time trends (i.e. ANOVA effects), supported by indices of the response trends (e.g. iAUC, time to peak). Bloods drawn pre-biopsy, pre-OGTT, and then 15 minutely for 120 minutes, and then 10 minutely after the ad libitum meal test.
Measured: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes (please note: may measure copeptin as a marker of arginine vasopressin)
Ghrelin Response
Primary analysis is time trends (i.e. ANOVA effects), supported by indices of the response trend (e.g. iAUC, time to peak). Due to funding limitations, we only took one 60 minute postprandial measure of ghrelin.
Measured: Measured on day 5 on both trial arms, using the blood sample drawn before the participant starts eating the buffet and the subsequent post-buffet blood samples
Energy Intake
Differences in energy intake between the hypohydrated and rehydrated groups (two-tailed t-test)
Measured: Measured on day 5 on both trial arms from the pasta test meal
Metabolic Rate
Comparing respiratory quotient and metabolic rate
Measured: Using the metabolic rate data collected on day 5 on both trial arms
Subjective Appetite Ratings
Comparing appetite response. Scales were visual analogue scales of hunger, fullness, how much you feel you can eat, thirst, and desire for sweet, salty, savoury and fatty foods. Scales were 0-100 mm vertical lines which participants marked where 0 = not at all/no desire and 100 = extremely/very high desire)
Measured: Collected on day 5 of both trial arms during the buffet
Muscle Volume
Comparing muscle size in the dehydrated and rehydrated state.Taken from the pQCT scans
Measured: pQCT scans on day 4 of the trial before the dehydration protocol in the heat tent, and on day 5 before the OGTT
Body Water Content
Taken from bioelectrical impedance weighing scales
Measured: Daily (i.e. 5 consecutive days for each trial arm)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2016 (estimated)
- Study startJul 2016
- Primary completionJan 2017
- Study completionJan 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bath
- Sponsor type
- University, hospital or other
- Collaborators
- University of Bristol, Loughborough University, European Hydration Institute, Economic and Social Research Council, United Kingdom, Lund University
- Responsible party
- Principal investigator, Harriet Carroll, University of Bath
- Investigators
- Harriet A Carroll, MRes, Principal investigator, University of Bath
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02841449
- Sponsor's protocol ID
- 16/SW/0057
- Status last verified
- Jun 2020
- First submitted
- 7 Jul 2016
- Last updated
- 22 Jun 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- Yes: Anonymised data will be shared
Publications
Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015 May;58(5):1081-90. doi: 10.1007/s00125-015-3496-9. Epub 2015 Jan 27.
PubMed 25622862Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L; D.E.S.I.R. Study Group. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011 Dec;34(12):2551-4. doi: 10.2337/dc11-0652. Epub 2011 Oct 12.
PubMed 21994426Keller U, Szinnai G, Bilz S, Berneis K. Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. Eur J Clin Nutr. 2003 Dec;57 Suppl 2:S69-74. doi: 10.1038/sj.ejcn.1601904.
PubMed 14681716Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes. 1979 May;28(5):503-8. doi: 10.2337/diab.28.5.503.
PubMed 108167
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Hydration Status on Glycemic Control and Appetite Regulation
- ClinicalTrials.gov ID
- NCT02841449
- Acronym / sponsor ID
- 16/SW/0057
- Conditions
- Healthy
- Keywords
- Hydration, Glycemic control, Appetite, Endocrinology
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- University of BathUniversity, hospital or other
- Collaborators
- University of Bristol, Loughborough University, European Hydration Institute, Economic and Social Research Council, United Kingdom, Lund University
- Study start
- Jul 2016 (actual)
- Primary completion
- Jan 2017 (actual)
- Study completion
- Jan 2017 (actual)
- First posted
- 22 Jul 2016 (estimated)
- Results
- Posted 22 Jun 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate whether hydration status affects blood sugar control and appetite regulation. In order to do this, participants will undergo a monitoring phase whereby their weight, diet and physical activity are monitored, followed by a dehydration protocol involving fluid restriction and sitting in a heat tent. In one arm of the trial, participants will remain dehydrated for the remainder of the day (i.e. after the heat tent) by having their fluid intake restricted, and in the other arm of the trial, participants will be rehydrated by consuming the necessary amount of plain water. All participants will undergo both arms of the trial, the order of which will be chosen randomly.
Several measures will be taken throughout the trial. Before participants go into the heat tent, they will provide a urine sample (for baseline hydration status as indicated by urine osmolality), a blood sample (for glucose, insulin, arginine vasopressin,/copeptin, ghrelin and serum osmolality and plasma volume), and have a peripheral quantitative computer tomography scan of their thigh to indicate muscle size. On the day proceeding the heat tent, participants will have these measures repeated, along with metabolic rate before consuming a 75 g glucose drink, followed by 15 minutely blood samples and hourly metabolic rate measures for 120 minutes (i.e. an oral glucose tolerance test; OGTT). Following this, participants will be presented with a large bowl of pasta and sauce and will be instructed to eat until satisfied (maximum 30 min). Blood samples will be taken every 10 minutes for 60 minutes following the meal.
Participants also have the option to opt-in to have a muscle biopsy taken. This will be taken before and ~120 minutes after the glucose drink.
Detailed description
The aim of this study is to investigate whether hydration status affects blood sugar control and appetite regulation. This will be a randomised crossover trial with two trial arms separated by 5-35 days. Each trial arm consists of five days in total, with the only difference between the trial arms being the amount of fluid consumed after the heat tent on day 4 (as described below).
Days 1-3 of each trial arm are the monitoring phase. Participants will be given a chest mounted activity monitor (ActiHeart TM), some body mass scales, a food diary with food weighing scales and three urine sample pots. Participants will be required to provide a urine sample upon waking, and note their weight before eating. The activity monitor will need to be worn from midnight on day 1 in order to gauge three full 24-h periods of activity. The food diary will also start at this point; participants will be required to weigh and record all their food and beverages (including recording the leftovers). On day 3 of the monitoring phase, participants will be required to continue their normal daily routine, however they will be provided with a set amount of water to consume (40 mL/kg lean body mass) in order to standardize baseline hydration status. No food or fluid will be allowed to be consumed after 2200 h on day 3.
On day 4, participants will take the same measures (weight and urine sample) and will arrive at the university in a fasted state (i.e. no food or fluid). A blood sample will be drawn from an antecubital vein followed by a peripheral quantitative computer tomography (pQCT) scan of the thigh. After the blood sample and scan, participants may eat food from a list of low water-content foods only for the rest of the day. At approximately midday (flexible depending on the participants' availability, but matched on both trial arms), participants will be weighed again, and placed in a heat tent (40-50 degrees Celsius) until they lose 1 % of their pre-heat tent weight or for a maximum of one hour (whichever comes first). On the second trial arm, participants will be matched by percentage of body mass loss, even if this requires spending more or less time in the heat tent, but still no more than one hour.
After the heat tent, participants will receive a salty meal in order to facilitate fluid absorption/retention. This will be matched in both trial arms in order to reduce confounding. In the dehydration trial arm, participants will be provided with 3 mL/kg lean body mass of plain water to consume for the rest of the day. In the rehydration trial arm, participants will be given 40 mL/kg lean body mass plus 150 % of their body mass losses from the heat tent. This will be metered out throughout the day to maximise rehydration. Thus the amount of water consumed on day 4 after the heat tent is the only discernible difference between the trial arms, with everything else matched. In both trial arms only plain water (i.e. no caffeine or alcohol) will be allowed to be consumed, and only foods from the dry food list can be eaten. This will be matched on the subsequent trial arm. No food or fluid after 2200 h on day 4.
On the fifth day of each trial arm, participants will be required to attend the laboratory at approximately 0730 h (± 1 h). A urine sample will be collected, along with body mass. Another pQCT scan of the thigh will be taken and participants' metabolic rate will be measured using the Douglas bag method. As part of the trial, participants are able to opt-in for a muscle biopsy. If they have opted-in, a muscle biopsy will be taken after the pQCT scan. This will involve a local anesthetic (Lidocaine), making a small incision using a scalpel, then obtaining a muscle sample using the Bergstrom technique. Participants will then be fitted with a cannula, and their hand will be placed in a 60 degree Celsius hotbox for five minutes, after which a baseline blood sample will be drawn. Participants will be given a 75 g glucose drink to consume within five minutes. Whilst remaining rested, a researcher will draw a 10 mL blood sample every 15 minutes for 120 minutes, with approximately 10 mL saline infused after each blood sample drawn. Metabolic rate will be measured at 0 (pre-OGTT), 60 and 120 minutes. For the participants who opted-in for the muscle biopsy, another one will be taken after 120 minutes.
Participants will then be presented with some computer based appetite assessing psychological inventories to assess subconscious food preferences. These tests are pilot data for future research. Following this, participants will be presented with a pasta meal, with the instruction to eat until satisfied for a maximum of 30 minutes. After 30 minutes, a blood sample will be drawn, followed by 10 minutely samples for 60 minutes. Visual analogue scales for subjective appetite ratings will be taken pre-meal, immediately, post-meal, then at 30 and 60 minutes post-meal. The cannula will then be removed.
The sample size required for this trial is 16 participants, calculated using pilot data which assessed blood glucose control after being dehydrated and rehydrated. Based on that pilot study, hydration status resulted in a marked difference in the rate of return to fasted glycaemia. This primary conclusion was supported by a magnitude of effect 45 minutes post-oral glucose tolerance test (D = 1.1 mmol/l). The standard deviation at this time point in the control (normal hydration) group was also 1.1 mmol/l, resulting in an effect size (d) of ≈1. To provide a 95 % power (beta level) to detect this effect at an alpha level (p) of less than or equal to 0.05 using a 2--tailed paired t--test will require ~16 participants.
If any participant does not complete the study (i.e. they have missing data), their data will not be included in the analysis. In other words, the analysis plan will be per protocol (completers only). The statistical techniques used will be linear modelling with post-hoc t-tests corrected for multiple comparisons where relevant. However, until the final dataset has been obtained, the statistical tests may be subject to change (e.g. if data are non-parametric).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hypohydrated | Experimental | Behavioral: HypohydratedAfter being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL]) |
| Rehydrated | Experimental | Behavioral: RehydratedAfter being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL). |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Healthy male or female
- Aged 18-60 years
- Able and willing to give informed consent
Key exclusion criteria (5 listed)
- Any known metabolic or glucose disorder
- Taking necessary medication (other than contraceptives) or supplements that are known to affect glycaemic control (e.g. chromium, PUFAs)
- Current alcohol or drug dependency
- Aged < 18 years, or > 60 years; pregnant or breastfeeding
- Any other factors which are deemed to have the potential to cause harm to the participant and/or could introduce bias into the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HypohydratedParticipants remain hypohydrated after the heat tent procedure | Behavioural | Hypohydrated |
| RehydratedParticipants rehydrate after the heat tent procedure | Behavioural | Rehydrated |
Primary outcome
Glycemic Response
Time frame: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes
Primary analysis is time trends (i.e. ANOVA effects), supported by indices of the glycemic response (e.g. iAUC, time to peak). Blood was taken pre-muscle biopsy (if participants opted in for a muscle biopsy), before consuming the glucose drink (after the biopsy, where applicable), then at 15 minutely samples for 120 minutes. After the meal test, blood was drawn at 10 minutely intervals for 60 minutes, starting 30 minutes after commencement of eating.
8 secondary outcomes
Insulinemic Response
Time frame: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes
Arginine Vasopressin and Copeptin Response
Time frame: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes (please note: may measure copeptin as a marker of arginine vasopressin)
Ghrelin Response
Time frame: Measured on day 5 on both trial arms, using the blood sample drawn before the participant starts eating the buffet and the subsequent post-buffet blood samples
Energy Intake
Time frame: Measured on day 5 on both trial arms from the pasta test meal
Metabolic Rate
Time frame: Using the metabolic rate data collected on day 5 on both trial arms
Subjective Appetite Ratings
Time frame: Collected on day 5 of both trial arms during the buffet
Muscle Volume
Time frame: pQCT scans on day 4 of the trial before the dehydration protocol in the heat tent, and on day 5 before the OGTT
Body Water Content
Time frame: Daily (i.e. 5 consecutive days for each trial arm)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 25622862Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015 May;58(5):1081-90. doi: 10.1007/s00125-015-3496-9. Epub 2015 Jan 27.
- Background: PubMed 21994426Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L; D.E.S.I.R. Study Group. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011 Dec;34(12):2551-4. doi: 10.2337/dc11-0652. Epub 2011 Oct 12.
- Background: PubMed 14681716Keller U, Szinnai G, Bilz S, Berneis K. Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. Eur J Clin Nutr. 2003 Dec;57 Suppl 2:S69-74. doi: 10.1038/sj.ejcn.1601904.
- Background: PubMed 108167Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes. 1979 May;28(5):503-8. doi: 10.2337/diab.28.5.503.
- Individual participant dataSharing planned: Yes. Anonymised data will be shared
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Harriet A Carroll, MRes principal investigator
University of Bath
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hypohydrated and Rehydrated in people with Healthy, run by University of Bath at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jun 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glycemic Response (time frame: Measured on day 5 on both trial arms, using the blood sample drawn before the glucose beverage is consumed and the blood samples drawn for the subsequent 120 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02841449, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2020.